Odonate Therapeutics, Inc. (NASDAQ: ODT) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers

On November 19, 2018, the board of directors of Odonate Therapeutics, Inc. (the “Company”) promoted John G. Lemkey, who previously served as Chief Financial Officer, to Chief Operating Officer and Michael S. Hearne, who previously served as Vice President of Finance and Accounting, to Chief Financial Officer. Effective on Mr.Hearne’s promotion, the board of directors appointed Mr.Hearne to serve as the Company’s principal financial officer and principal accounting officer. Mr. Hearne succeeds Mr. Lemkey in those roles.

Information about Mr. Lemkey, including a biographical summary, is included in the Company’s definitive proxy statement for the 2018 Annual Meeting of Stockholders on Schedule 14A filed with the U.S. Securities and Exchange Commission on June 1, 2018.

Mr. Hearne, 56, previously served as the Company’s Vice President of Finance and Accounting from 2015 to 2018. Since 2015, Mr. Hearne has also served as Chief Financial Officer of Tang Capital Management, LLC, a life sciences-focused investment company and an affiliate of the Company. From 2014 to 2015, Mr. Hearne served as a Partner at Weaver & Tidwell, LLP. From 2008 to 2014, Mr. Hearne had his own financial consulting business. From 2000 to 2008, Mr. Hearne served as a Partner at Rothstein Kass & Company, P.C. Mr. Hearne started his public accounting career at Coopers & Lybrand in 1988. Mr. Hearne received a B.S. degree in accounting and a Masters of Accountancy, Taxation from Brigham Young University and is a Certified Public Accountant (inactive) in the state of California.